Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses.

Tariq Jamal SiddiqiDavid CherneyHasan Fareed Siddiqui Tazeen Hasan Jafar James L JanuzziMuhammad Shahzeb KhanAdeera Levin Nikolaus MarxJanani RangaswamiJeffrey TestaniMuhammad Shariq UsmanChristoph Wanner Faiez ZannadJaved Butler

Published in: Journal of the American Society of Nephrology : JASN (2024)

SGLT2i improved kidney outcomes in cohorts with heart failure, chronic kidney disease, and type 2 diabetes mellitus, and these effects were consistent across patients with different combinations of these comorbidities.

Keyphrases

heart failure
chronic kidney disease
meta analyses
systematic review
end stage renal disease
glycemic control
randomized controlled trial
cardiovascular disease
skeletal muscle
adipose tissue
cardiovascular risk factors
metabolic syndrome
insulin resistance
peritoneal dialysis